SM
UTHR icon

SG3 Management’s United Therapeutics UTHR Stock Holding History

SG3 Management’s Portfolio UTHR Stock Details UTHR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-750
Closed -$209K – 167
2022
Q4 		$209K Buy
+750
New +$189K 0.03% 160
2022
Q2 		– Sell
-12,500
Closed -$2.54M – 847
2022
Q1 		$2.24M Buy
+12,500
New +$2.38M 0.06% 282
2021
Q4 		– Sell
-6,000
Closed -$1.11M – 1303
2021
Q3 		$1.11M Buy
+6,000
New +$1.18M 0.03% 443

Other funds holding UTHR

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return

SG3 Management's UTHR Position: Q1 2023 in Review

SG3 Management sold out of United Therapeutics (UTHR) in Q1 2023, closing a stake of 750 shares — an estimated $209K sold.

SG3 Management first reported a position in UTHR in Q3 2021 and held it in 3 quarters. The position peaked at $2.24M in Q1 2022. 506 funds tracked by Wall St. Rank hold UTHR as of Q1 2023.

  • SG3 Management reported no remaining United Therapeutics position as of Q1 2023 after selling out during the quarter.
  • SG3 Management sold 750 United Therapeutics shares in Q1 2023, an estimated $209K.
  • SG3 Management first reported a position in United Therapeutics in Q3 2021 and held it in 3 quarters.
  • SG3 Management's United Therapeutics position peaked at $2.24M in Q1 2022.
  • 506 funds tracked by Wall St. Rank held United Therapeutics as of Q1 2023.

Based on SG3 Management's 13F filing for Q1 2023, filed 15 May 2023.